ClinicalTrials.gg
Active, not recruitingNCT07238647Updated May 12, 2026

A Trial of HRS-5817 in Obese Participants

An Early Phase 1 interventional study of HRS-5817 and HRS-5817 in Obesity, sponsored by Atridia Pty Ltd.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Atridia Pty Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Early Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. — 8 open to participants now, 13 under way, 4 of them phase 3. Obesity · Jiangsu HengRui Medicine Co., Ltd..

Planned enrollment
22nd of 24
40 · median 130
Started
2026
with 6 others
Phase 1
11 of 24
4 open now
Primary completion
2027-01
later than 5 of 12 live
Registered
16th of 24
by date

Among the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., this one is the 22nd largest by planned enrollment, is one of 7 that started in 2026, is one of 11 in phase 1, reaches primary completion later than 5 of the 12 other live ones, and was the 16th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Obesity by Jiangsu HengRui Medicine Co., Ltd., or all of them as a file.
02

Study summary

The purpose of this study is to assess safety, PK, Pharmacodynamic and immunogenicity profile of a single dose of HRS-5817 in obese participants

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged between 18 to 55 years of age (inclusive)
  2. Participants with (BMI) between 30.0 kg/m2 (inclusive) to 40.0 kg/m2 (inclusive) at screening.
  3. Ability to understand the trial procedures and possible adverse events, volunteer to participate in the trial, and provide written , be able to comply with all the requirements, and able to complete the study.

Negative pregnancy test for women of (WOCBP) at baseline. Men and WOCBP must agree to take highly effective methods

Exclusion criteria

Exclusion Criteria:

1. History or evidence of disorders 2. Individuals with a weight change of more than 5kg within 3 months prior to the screening.

  1. Participant with a history of or current endocrine disorders that may significantly influence body weight (e.g., Cushing's syndrome, hypothyroidism, hyperthyroidism), or with obesity resulting from pharmacotherapy, monogenic mutations, or hereditary obesity syndromes.
  2. Any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
  3. Use of any GLP-1 receptor agonists (including but not limited to Liraglutide, Beneglitide, Semaglutide, and Tirzepatide, etc.) or any other prescription medications, OTC drugs and dietary supplements for weight loss (including but not limited to Orlistat, Naltrexone/Bupropion, Phentermine/Topiramate, ect.). within 3 months prior to screening, and no planned use for the study duration.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Experimental: HRS-5817 dose level 1

    Single dose of HRS-5817/placebo given subcutaneously (dose level 1)

    Drug: HRS-5817

  • Experimental
    Experimental: HRS-5817 dose level 2

    Single dose of HRS-5817/placebo given subcutaneously (dose level 2)

    Drug: HRS-5817

  • Experimental
    HRS-5817 dose level 3

    Single dose of HRS-5817/placebo given subcutaneously (dose level 3)

    Drug: HRS-5817

  • Experimental
    HRS-5817

    Single dose of HRS-5817/placebo given subcutaneously (dose level 4)

    Drug: HRS-5817

Interventions

  • DrugHRS-5817

    Single dose of HRS-5817/placebo given subcutaneously (dose level 1 )

  • DrugHRS-5817

    Single dose of HRS-5817/placebo given subcutaneously (dose level 2 )

  • DrugHRS-5817

    Single dose of HRS-5817/placebo given subcutaneously (dose level 3 )

  • DrugHRS-5817

    Single dose of HRS-5817/placebo given subcutaneously (dose level 4)

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events

    Number of participants with Adverse events and Serious adverse events

    Time frame: Day 253

Secondary outcomes

  1. Pharmacokinetics - Cmax

    Maximum observed plasma concentration (Cmax)

    Time frame: Day 253

  2. Pharmacokinetics - AUC₀-t

    Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀-inf)

    Time frame: Day 253

  3. Pharmacokinetics - Tmax

    Time to reach maximum observed plasma concentration (Tmax)

    Time frame: Day 253

  4. Pharmacokinetics - t½

    Terminal elimination half-life (t½)

    Time frame: Day 253

  5. Immunogenicity - Anti-Drug Antibody (ADA)

    Incidence and onset time of anti-drug antibody (ADA)

    Time frame: Day 253

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jan 2027, 12 months after the start.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 12 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2025
First posted
Nov 20, 2025
StartActual
Jan 5, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Jan 30, 2027
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07238647
Lead sponsor
Atridia Pty Ltd.
Responsible party
Sponsor
First posted
Nov 20, 2025
Start date
Jan 5, 2026
Primary completion
Jan 30, 2027 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
May 12, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion